Hong Kong · Delayed Price · Currency is HKD Qyuns Therapeutics Company Description
Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in China.
Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor, which completed Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra that is in Phase III clinical trial for treating prurigo nodularis.
The company also develops QX001S, which is an IL-12/L-23p40 inhibitor for psoriasis under the SAILEXIN brand.
In addition, the company develops QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin that is in Phase Ib clinical trial to treat moderate-to-severe asthma and chronic obstructive pulmonary disease; and QX004N, an IL-23p19 inhibitor, which is in Phase II clinical trial to treat psoriasis and Crohn’s disease.
The company also develops QX027N, an anti-TSLPxIL-13 bispecific antibody that targets AD and asthma indications; QX030N, a IL-23p19/TL1A clinical stage long-acting bispecific antibody for the treatment of inflammatory bowel diseases; QX031N, a clinical stage TSLP/IL-33 long-acting bispecific antibody for the treatment of chronic obstructive pulmonary disease and asthma; and QX035N, a bispecific antibody for the treatment of respiratory and dermatology diseases.
Further, it manufactures and sells pharmaceutical products; and provides technical consultation services.
Qyuns Therapeutics Co., Ltd. was incorporated in 2015 and is headquartered in Taizhou, China.
| Country | China |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 337 |
| CEO | Jiwan Qiu |
Contact Details
Address: Building 1 Taizhou China | |
| Phone | 86 523 8027 6311 |
| Website | qyuns.net |
Stock Details
| Ticker Symbol | 2509 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000069W9 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jiwan Qiu | GM and Chairman of the Board |
| Yiliang Wu | GM of Cellularforce and Executive Director |
| Weidong Lin | Deputy GM and Executive Director |
| Yanbao Hu | Board Secretary and Joint Company Secretary |
| King Yin Tang | Joint Company Secretary |